[AMAG] AMAG Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 35.8 Change: 1 (2.87%)
Ext. hours: Change: 0 (0%)

chart AMAG

Refresh chart

Strongest Trends Summary For AMAG

AMAG is in the long-term down -84% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: AMAG Pharmaceuticals, Inc. develops and commercializes specialty pharmaceutical products. The company markets Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It markets Feraheme in the United States and Canada; and as Rienso in the European Union. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as an IV iron rep

Fundamental Ratios
Shares Outstanding EPS1.11 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 385.93% Sales Growth - Q/Q38.41% P/E14.77
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA11.63% ROE26.74% ROI15.98%
Current Ratio1.71 Quick Ratio1.61 Long Term Debt/Equity1.51 Debt Ratio0.45
Gross Margin81.03% Operating Margin31.1% Net Profit Margin65.25% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities183.64 M Cash From Investing Activities-284.74 M Cash From Operating Activities71.69 M Gross Profit104.2 M
Net Profit33.26 M Operating Profit61.12 M Total Assets1.64 B Total Current Assets555.48 M
Total Current Liabilities323.97 M Total Debt483.2 M Total Liabilities926.3 M Total Revenue123.88 M
Technical Data
High 52 week25.65 Low 52 week10.34 Last close10.34 Last change-4.08%
RSI40.26 Average true range0.72 Beta0.76 Volume768.3 K
Simple moving average 20 days-8.89% Simple moving average 50 days-14.38% Simple moving average 200 days-41.9%
Performance Data
Performance Week-10.32% Performance Month-13.18% Performance Quart-38.12% Performance Half-56.92%
Performance Year-21.96% Performance Year-to-date-31.93% Volatility daily4.01% Volatility weekly8.97%
Volatility monthly18.39% Volatility yearly63.7% Relative Volume235.39% Average Volume747.72 K
New High New Low

News

2019-11-16 08:18:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

2019-11-13 14:14:21 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

2019-11-13 08:00:00 | AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

2019-11-07 17:44:39 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

2019-11-07 11:44:09 | Hedge Funds Are Still Bullish On AMAG Pharmaceuticals AMAG

2019-11-06 06:18:11 | AMAG Sees Hammer Chart Pattern: Time to Buy?

2019-11-04 11:18:04 | AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates

2019-11-03 22:36:08 | Edited Transcript of AMAG earnings conference call or presentation 1-Nov-19 12:00pm GMT

2019-11-01 12:25:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

2019-11-01 08:15:12 | AMAG Pharmaceuticals AMAG Reports Q3 Loss, Lags Revenue Estimates

2019-11-01 07:00:05 | AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate Update

2019-10-31 11:36:03 | The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

2019-10-31 10:55:00 | Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. AMAG

2019-10-30 16:23:30 | Biotech Dives After Panel Votes To Pull Its Drug Following Failed Test

2019-10-30 10:56:02 | Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More

2019-10-30 10:15:02 | What's in Store for GW Pharmaceuticals GWPH in Q3 Earnings?

2019-10-30 09:20:17 | AMAG Pharmaceuticals Falls 25% After FDA Recommends Removing Makena From The Market

2019-10-29 21:40:00 | AMAG Reports on FDA Advisory Committee Meeting for Makena® Hydroxyprogesterone Caproate Injection

2019-10-29 17:05:51 | FDA committee votes to pull labor-halting drug from market

2019-10-29 10:29:02 | AMAG Pharmaceuticals, Inc. AMAG Shares March Higher, Can It Continue?

2019-10-29 10:25:02 | Is a Beat in Store for Amarin AMRN This Earnings Season?

2019-10-29 07:03:36 | AMAG Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss the Results of the Makena PROLONG Trial

2019-10-28 16:21:41 | This Biotech Stock Popped — But Could The FDA Pull Its Key Drug?

2019-10-28 06:04:08 | Proxy fights reach 'frightening' level in life sciences, other industries, top attorney says

2019-10-27 12:56:58 | The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

2019-10-25 10:30:02 | AMAG Pharmaceuticals AMAG Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2019-10-25 10:19:22 | AMAG Pharmaceuticals Announces the Publication of the PROLONG Trial Evaluating 17-OHPC in the American Journal of Perinatology

2019-10-24 08:00:05 | AMAG Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Friday, November 1, 2019 at 8:00 a.m. ET

2019-10-11 08:00:00 | AMAG Pharmaceuticals Announces the Publication of the Phase 3 Vyleesi™ Bremelanotide Injection Data in Obstetrics & Gynecology

2019-10-08 08:45:37 | UPDATE 2-Amag settles with activist Caligan, adds two board directors

2019-10-08 08:00:00 | AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP

2019-09-28 09:05:00 | Here's Why AMAG Pharmaceuticals NASDAQ:AMAG Can Afford Some Debt

2019-09-26 08:00:00 | Caligan Partners Issues Letter to AMAG Shareholders

2019-09-25 08:00:00 | AMAG Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

2019-09-23 08:00:00 | AMAG Files Definitive Consent Revocation Statement and Sends Letter to Shareholders

2019-09-20 08:44:07 | UPDATE 2-Camber Capital to discuss Amag's board composition with shareholders

2019-09-20 08:20:07 | Camber Capital says Amag Pharma's shares undervalued, seeks changes

2019-09-16 08:00:00 | Caligan Partners Launches Consent Solicitation Process and Sends Letter to AMAG Shareholders

2019-09-12 08:00:00 | AMAG Sends Letter to Shareholders

2019-09-06 09:31:01 | Why Is AMAG Pharmaceuticals AMAG Up 27.3% Since Last Earnings Report?

2019-09-05 06:24:51 | Activist investor pushes for ex-Goop CEO, others to join board of Waltham drugmaker Amag

2019-09-04 17:56:11 | AMAG Urges Stockholders to Take No Action on Caligan Partners’ Consent Solicitation Materials

2019-09-04 09:45:46 | Activist Investor Seek Four Board Seats at Amag Pharmaceuticals

2019-08-27 08:00:00 | AMAG Pharmaceuticals Announces Commercial Availability of Vyleesi™ Bremelanotide Injection

2019-08-20 08:00:00 | AMAG Pharmaceuticals Announces Grant of Inducement Awards Under NASDAQ Listing Rule 5635c4

2019-08-16 10:42:02 | Palatin's PTN to Report Q4 Earnings: What's in the Cards?

2019-08-16 06:20:45 | Gene therapies to test FDA's approach to regulating drugs after launch, experts say

2019-08-15 14:23:00 | [video]New York Investment Firm Discloses 10.3% Amag Stake, May Propose Changes

2019-08-14 13:39:58 | Have Insiders Been Buying AMAG Pharmaceuticals, Inc. NASDAQ:AMAG Shares?

2019-08-13 11:42:22 | Jim Cramer Shares His Thoughts On Delta Air Lines, Okta And More